This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patenting human genes and mutations: A personal perspective
Go to paperABSTRACT:
The Journal of Commercial Biotechnology is a unique forum for all thos…
Patenting human genes and mutations: A personal perspective Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT: The recent approval of a follow-on version of Pfizer’s Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies…
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
As an offshoot of PatentStat, I’ve assembled a set of graphs of patent inventor locations, focusing in 33 industry sectors.
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT: This paper analyses the recent ruling in Kinik Co. v. Int’l Trade Comm’n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings before the US International Trade Commission under the Tariff Act of 1930 (19 USC §1337(a)) – particularly those concerning the importation of products derived from practising US patented processes abroad.
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The regulatory system in the EU and further afield
Go to paperABSTRACT: The regulation of modern biotechnology began almost as soon as the potential ben…
The regulatory system in the EU and further afield Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
EU Financial accounts reports
Go to paperABSTRACT: Presents updates on the 2000 financial results of several biotechnology and pharmaceutical firms in Eu…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Conflict of interest in academic research
Go to paperABSTRACT: The potential for conflict of interest in research can occur whenever a faculty member’s …
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A new season for biotechnology in Europe
Go to paperABSTRACT: Comments on the status of the biotechnology industry in Europe as of March 2002. Research s…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Welcome to Biotech Nation
Go to paperABSTRACT: Welcome to Biotech NationMoira A. Gunn, PhDAMACOM, New York, NY;ISBN: 978 0814409237; 2007; 258pp; hardbac…
Get new actionable insights and updates from BiotechBlog
